Evaluating the role of albumin in the prognosis of severely burned patients
Albumin and Prognosis of Severely Burned Patients Retrospective, Prospective, Observational Study for the BurnICU Group of ESICM
This study looks at how giving albumin to adults with severe burns right after they are admitted affects their chances of surviving and developing serious complications.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris, France) |
| Trial ID | NCT04264065 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on adult patients with severe burns covering more than 30% of their total body surface area (TBSA). It aims to collect and analyze data on the incidence of mortality, severe acute renal failure, and acute respiratory distress syndrome in these patients, particularly examining the impact of albumin administration during the first 24 hours of resuscitation. The study will follow participants for 90 days post-admission to gather insights that could inform future interventional trials regarding albumin's role in burn management.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with severe burns greater than 30% TBSA admitted to the ICU within 12 hours of injury.
Not a fit: Patients who may not benefit include those who are pregnant, have limitations on active therapeutics, or are over 80 years old.
Why it matters
Potential benefit: If successful, this study could improve the management and outcomes of severely burned patients by providing evidence for the use of albumin in their initial treatment.
How similar studies have performed: While the use of albumin in burn management is controversial, existing data suggest potential benefits, indicating that this approach may not be entirely novel but requires further investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients over 18 years of age * Burns \> 30% SCT * Patients admitted to the ICU within 12 hours of a burn. Exclusion Criteria: * Pregnancy * Patients with a limitation of active therapeutics on admission to BICU * Pre-hospital cardiac arrest * Moribund patients: pre-hospital cardiac arrest, CBS burn \>95%. * Age \>80 years
Where this trial is running
Paris, France
- Hopital saint Louis — Paris, France, France (Recruiting)
Study contacts
- Principal investigator: François Dr DEPRET, MD — Hospital Saint Louis (AP-HP)
- Study coordinator: François Dr DEPRET, MD
- Email: francois.depret@aphp.fr
- Phone: (1)42 49 95 70
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.